Protected: Is Prior Authorization a Blessing or a Curse?
There is no excerpt because this is a protected post.
There is no excerpt because this is a protected post.
There is no excerpt because this is a protected post.
There is no excerpt because this is a protected post.
There is no excerpt because this is a protected post.
Chronic wounds demand clinicians willing to act outside of their defined role, not because the system incentivizes it, but because without it, the wound will not heal. The post The Silent Epidemic: Why Diabetic Foot Ulcers Have Been Overlooked for Three Decades appeared first on MedCity News.
We are on the cusp of an age of anticipatory medicine, an explosion in our ability to read the body’s signals and catch the killers before they do their damage. The post Reading the Body’s Signals: AI’s Ultimate Healthcare Opportunity appeared first on MedCity News.
In the summer of 2024, Emilie and Justin Solomon found themselves on a top-secret mission in Greece. Their family and friends thought the adventure-loving couple was on another jet-setting vacation, but they were keeping something else under wraps: They had turned off their phone locations to hide visits to a Greek clinic where they were…
On an August morning two years ago, Meredith Melville was crossing Piedmont Avenue in Oakland, California, to meet a friend at a cafe. While in the crosswalk, she noticed a car some distance away. Perhaps she misjudged its speed, she said, because she’d walked only partway across the street when the car, a Toyota sedan,…
In the thick of his competitive reelection race in Michigan, Republican Rep. Tom Barrett joined Health and Human Services Secretary Robert F. Kennedy Jr. at a sprawling 400-acre apple orchard, farm, and winery. They touted Trump administration efforts to improve the American diet, including the removal of some artificial dyes from processed foods. “We had…
AstraZeneca and Amgen drug Tezspire met the goals of a Phase 3 test in eosinophilic esophagitis (EoE), a chronic disorder whose only approved biologic therapy is Sanofi’s Dupixent. An approval for Tezspire in EoE would be its third indication, bolstering sales of the blockbuster product. The post AstraZeneca, Amgen Drug Moves Closer to Competing With…